Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EBITDA (2020 - 2025)

Journey Medical (DERM) has disclosed EBITDA for 6 consecutive years, with -$1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 47.17% year-over-year to -$1.5 million, compared with a TTM value of -$5.5 million through Sep 2025, up 69.5%, and an annual FY2024 reading of -$13.7 million, down 559.77% over the prior year.
  • EBITDA was -$1.5 million for Q3 2025 at Journey Medical, up from -$2.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $17.2 million in Q3 2023 and bottomed at -$13.8 million in Q2 2021.
  • Average EBITDA over 5 years is -$4.5 million, with a median of -$3.3 million recorded in 2025.
  • The sharpest move saw EBITDA crashed 5391.21% in 2021, then skyrocketed 281.68% in 2023.
  • Year by year, EBITDA stood at -$9.1 million in 2021, then fell by 10.36% to -$10.0 million in 2022, then skyrocketed by 78.95% to -$2.1 million in 2023, then soared by 206.18% to $2.2 million in 2024, then plummeted by 168.44% to -$1.5 million in 2025.
  • Business Quant data shows EBITDA for DERM at -$1.5 million in Q3 2025, -$2.9 million in Q2 2025, and -$3.3 million in Q1 2025.